Investigational Drug for the treatment of Decompensated Cirrhosis
Catherine Frenette, MD
This study is evaluating how safe and effective the investigational drug Emricasan may be in delaying or improving survival for patients with Decompensated NASH cirrhosis. Participation will last up to 48 weeks and requires study visits every 4 weeks.
Be 18 years or older
Have been diagnosed with cirrhosis due to NASH confirmed by liver biopsy
Have evidence of severe decompensation as determined by your doctor
Currently be taking a blood thinning medication
Have unstable diabetes
Have had bariatric within 1 year
Be pregnant or planning a pregnancy
Emricasan may help to block an enzyme that plays a role in the process that causes liver scarring and damage. Patients will be randomized to receive either 5mg emricasan, 25mg emricasan, or a matching placebo. Study medication will be taken twice daily in conjunction with local standard of care.